- Home
- BIRK vs ROIV Comparison
BIRK vs ROIV Comparison
Compare BIRK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIRK | ROIV |
|---|---|---|
| Founded | 1774 | 2014 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 20.7B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BIRK | ROIV |
|---|---|---|
| Price | $34.67 | $28.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $62.69 | $27.56 |
| AVG Volume (30 Days) | 2.0M | ★ 4.5M |
| Earning Date | 05-14-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $14.21 | $594.84 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.06 | $8.73 |
| 52 Week High | $57.39 | $30.33 |
Technical Indicators
Market Signals| Indicator | BIRK | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 56.22 |
| Support Level | $33.06 | $26.94 |
| Resistance Level | $42.19 | $30.33 |
| Average True Range (ATR) | 1.61 | 0.95 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 28.26 | 79.20 |
Price Performance
Historical ComparisonAbout BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.